Plain-English translation of NCT06253871 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called to see if it can safely and effectively treat advanced cancers that have specific HER2 alterations — including breast cancer, lung cancer, bladder cancer, colorectal cancer, and gastric cancer. The study will test the medication alone and in combination with other cancer treatments. Researchers will carefully watch for side effects and measure whether tumors shrink or stop growing.
Many patients with HER2-altered cancers stop responding to standard treatments, and there is a need for new options — especially medications that can reach cancer cells in the brain. This trial aims to find out if this medication can help patients whose cancers have become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth in cycles (either 14 or 21 days long), either alone or combined with other cancer drugs. The trial has four parts: the first part tests increasing doses to find the safest level, the second optimizes the best dose, the third expands to more patients with specific cancer types, and the fourth tests combinations with other treatments. You will have regular clinic visits for blood tests, imaging scans, and check-ins to monitor how you are responding and any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States